UBX Stock Overview
A biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Unity Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.17 |
| 52 Week High | US$2.17 |
| 52 Week Low | US$1.11 |
| Beta | 0.83 |
| 11 Month Change | -16.43% |
| 3 Month Change | -23.53% |
| 1 Year Change | -42.08% |
| 33 Year Change | -94.96% |
| 5 Year Change | -98.40% |
| Change since IPO | -99.30% |
Recent News & Updates
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?
Nov 05
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?
Jul 12Recent updates
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?
Nov 05Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?
Jul 12Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation
Mar 05Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
Nov 18UNITY Biotechnology falls 7% on reverse stock split
Oct 19Unity Biotechnology cuts stock sales agreement in half to $25M
Aug 19Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M
Aug 12A Look At Unity's UBX1325 Phase 1 Results
Jul 26Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently
Dec 22A Look Inside Unity Bio's Transition To An Ophthalmology Company
Nov 27Shareholder Returns
| UBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.7% | -6.5% | -1.0% |
| 1Y | -42.1% | 14.6% | 30.3% |
Return vs Industry: UBX underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: UBX underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| UBX volatility | |
|---|---|
| UBX Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: UBX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: UBX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Anirvan Ghosh | unitybiotechnology.com |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
Unity Biotechnology, Inc. Fundamentals Summary
| UBX fundamental statistics | |
|---|---|
| Market cap | US$19.54m |
| Earnings (TTM) | -US$21.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs UBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$18.39m |
| Gross Profit | -US$18.39m |
| Other Expenses | US$3.50m |
| Earnings | -US$21.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did UBX perform over the long term?
See historical performance and comparison